Apteka Exhibition Russian Health Care Week UFI Approved Event
To main
For exhibitors
For visitors

Bristol-Myers misleading HC in patent case


Bristol-Myers Squibb has told the Delhi high court that BDR Pharma’s application for compulsory licence of a generic version of cancer drug, dasatinib, has been rejected, as reported The Times of India.

However, BDR Pharma’s license application is still pending with the Patent Controller, a company official said.

Bristol-Myers Squibb is believed to be «misleading» the court which may «influence the final order," according to a lawyer who represents BDR Pharma.

Source: firstwordpharma.com

Back to the list

Invite partners to the exhibition
Facebook Youtube RSS Feed

Contacts Flashback Site map
119002 Moscow, Arbat str., 35, of. 423
Тel: +7 (495) 925-65-61/62
Fax: +7 (499) 248-07-34